The BOLD-MRI-related parameter ΔR2*, a surrogate marker for oxygen delivery via the blood, exhibited significant differences between luminal A and triple-negative breast cancers, as well as between Her2+ and triple-negative breast cancers (both p < 0.001; see Table 1). Here, ERBB2 is linked to triple-negative breast carcinoma.